Chinese biotech Innovent Biologics, Inc., backed by Singapore’s Temasek Holdings, is seeking to raise US$400 million to US$500 million in an initial public (IPO) offering in Hong Kong.
Temasek-Backed Biotech Firm Innovent Seeks To Raise Up To $500M In HK IPO appeared first on China Money Network.